GSK2881078

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Cachexia

Phase 1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses

CompletedNCT02045940

GlaxoSmithKlineCachexia

Start: 2014-01-20End: 2015-03-26Updated: 2018-07-24

Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078

CompletedNCT02567773

GlaxoSmithKlineCachexia

Start: 2015-09-30End: 2016-12-31Updated: 2017-03-06

Phase 2

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT03359473

GlaxoSmithKlineCachexia

Start: 2018-02-28End: 2019-11-19Updated: 2020-07-15

Related Papers

Qualitative interviews of patients with COPD and muscle weakness enrolled in a clinical trial evaluating a new anabolic treatment: patient perspectives of disease experience, trial participation and outcome assessments.

2024-04-202 citations

Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial

Thorax2022-10-2523 citations